|

JMT101 Clinical Trials

1 actively recruiting trial

Also known as: Recombinant Humanized Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Injection

Pipeline

Phase 3: 1

Top Sponsors

  • Shanghai JMT-Bio Inc.1

Indications

  • Previously Untreated Systematically NSCLC1
  • Harboring EGFR Sensitive Mutations NSCLC1
  • Locally Advanced or Metastatic Non-squamous NSCLC1
  • Lung Cancer1
  • Cancer1

Other1 trial

A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.